创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology ADCC platform: what are the key features

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-09 16:29
  • Views:

(Summary description)With the rapid development of the biopharmaceutical field, the importance of antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism in tumor immunotherapy has become increasingly prominent. In order to meet the growing research needs, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully built an in vitro pharmacodynamics platform, of which the ADCC platform has been widely recognized by the industry for its unique features and advantages. This article will introduce the main features of ADCC platform.

InnoModels Biotechnology ADCC platform: what are the key features

(Summary description)With the rapid development of the biopharmaceutical field, the importance of antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism in tumor immunotherapy has become increasingly prominent. In order to meet the growing research needs, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully built an in vitro pharmacodynamics platform, of which the ADCC platform has been widely recognized by the industry for its unique features and advantages. This article will introduce the main features of ADCC platform.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-07-09 16:29
  • Views:
Information

With the rapid development of the biopharmaceutical field, the importance of antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism in tumor immunotherapy has become increasingly prominent. In order to meet the growing research needs, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully built an in vitro pharmacodynamics platform, of which the ADCC platform has been widely recognized by the industry for its unique features and advantages. This article will introduce the main features of ADCC platform.
1、Diversified experimental service system
The ADCC platform of InnoModels has a diversified experimental service system, which can support the combination experiments of various types of tumor cells and immune cells. Whether it is tumor cell lines, primary tumor cells or genetically engineered cell lines, the platform can provide corresponding experimental conditions and technical support. This diversity provides a wide selection space for researchers to choose the most suitable cell type according to specific research needs.
2. Realistic simulation environment
In terms of experimental design, InnoModels' ADCC platform focuses on simulating the in vivo environment to more realistically reflect the actual situation of the ADCC process. The platform adopts advanced cell culture technology and flow cytometry technology, which can monitor and record the changes of cells in real time during the experimental process, effectively differentiate the target cells, count and calculate the proportion of apoptotic cells. This real simulation environment makes the experimental results more valuable and provides researchers with accurate and reliable data support.
3. Highly customizable
InnoModels' ADCC platform is highly customizable and can be tailored to the specific needs of researchers. This includes various aspects such as cell type, drug treatment, and experiment time. This flexibility enables the platform to meet the diverse needs of different researchers, providing powerful technical support for biomedical research.

 


4. Efficient Data Processing Capability
Equipped with an advanced data analysis system, the platform is able to automate the processing and analysis of experimental data, greatly improving the efficiency and accuracy of data processing. Researchers can understand the experimental results intuitively through the visualization report provided by the platform, so as to better guide the subsequent research work.
5、Professional technical team
The core team of InnoModels Biotechnology ADCC platform consists of a group of senior entrepreneurs, investors and professional managers in the industry, with rich experience in R&D, management, entrepreneurship, investment and capital operation. They have been working in the biomedical field for many years, and have in-depth understanding and rich practical experience in ADCC mechanism. This provides a solid guarantee for the stable operation of the platform and the reliability of the experimental results.
6、Extensive cooperation and communication
Focusing on communication and cooperation with industry peers, InnoModels Biotechnology actively participates in various academic conferences and seminars to share the latest research results and technological advances. At the same time, the platform has also established good cooperative relationships with famous enterprises and research institutions at home and abroad to jointly promote the development of the biomedical field.
In summary, with its diverse experimental services, realistic simulation environment, high customizability, efficient data processing capability and professional technical team, the InnoModels Biotechnology ADCC platform provides powerful technical support for biomedical research. In the future, with the continuous development of the biomedical field, the InnoModels Biotechnology ADCC platform will play a greater role in promoting the progress of biomedical research.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司